Physician profile
Weldon E Collins
NPI 1316063423
$8,250.85
in general payments reported to CMS, 2019-2025
24 companies · $1,446 in 2025
The $1,446 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,292 · 2020: $279 · 2021: $690 · 2022: $1,328 · 2023: $1,394 · 2024: $1,821 · 2025: $1,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,587 · Education: $74.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,587.42 |
| Education | $74.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,702.66 | 2019-2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $1,641.99 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Scientific Affairs, LLC | $740.12 | 2019-2022 | |
| Genzyme Corporation | $727.90 | 2019-2025 | |
| Amgen INC. | $658.52 | 2019-2025 | Otezla |
| Ucb, INC. | $396.17 | 2023-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $328.29 | 2022-2025 | Opzelura, Opzelura |
| Celgene Corporation | $279.26 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $268.66 | 2022-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $229.83 | 2019-2025 | |
| Lilly USA, LLC | $210.70 | 2019-2025 | Ebglyss |
| Arcutis Biotherapeutics, INC. | $181.67 | 2023-2025 | Zoryve |
| Pfizer INC. | $179.02 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $129.34 | 2023-2024 | Dupixent |
| Sun Pharmaceutical Industries INC. | $111.13 | 2021-2023 | Ilumya |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $104.95 | 2019 | |
| Dermavant Sciences, INC. | $78.29 | 2023 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $72.52 | 2019-2022 | |
| Epi Health, LLC | $71.40 | 2022 | |
| Mallinckrodt Hospital Products INC. | $54.28 | 2024-2025 | Acthar |
| Galderma Laboratories, L.P. | $27.84 | 2024-2025 | Aklief |
| Medtronic, INC. | $21.40 | 2025 | Nuvent |
| Leo Pharma INC. | $20.69 | 2024 | Adbry |
| Genentech USA, INC. | $14.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weldon Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.